Short-term Clinical Outcomes of Primary Total Hip Arthroplasty with the CoreHip Stem

The CoreHip Stem is a novel femoral stem introduced in 2021. It features a triple-taper design that enables three-dimensional load transmission and provides high rotational stability due to its rectangular cross-sectional geometry. This study aimed to retrospectively review the short-term clinical outcomes of primary total hip arthroplasty (THA) using the CoreHip Stem.

A total of 41 primary THA cases (17 men and 24 women; mean age, 66 years; mean follow-up period, 18 months) performed through a supine anterolateral approach at our institution between July 2024 and August 2025 were enrolled in this study. The evaluated parameters included operative time, intraoperative blood loss, the Japanese Orthopaedic Association (JOA) hip scores, perioperative complications, postoperative stem alignment, subsidence, stress shielding, spot welds, cortical hypertrophy, and radiolucent lines. Statistical analyses were performed using the t-test.

The mean operative time was 66.1 min, and the mean intraoperative blood loss was 202.2 mL. The mean JOA hip score improved from 44.9 points preoperatively to 95.2 points postoperatively. No perioperative complications were observed during the follow-up period. The stem survival rate was 100% at the final follow-up. No case showed obvious stem malalignment or subsidence of ≥2 mm. Grade I stress shielding was observed in five cases. Spot welds were identified in 30% of cases in Gruen zones 2 and 6 and in 27% of cases in zones 3 and 5. No other radiographic abnormalities were observed.

Past studies have shown favorable short- to mid-term clinical outcomes in THA cases using short tapered-wedge stems. The results of the present study were consistent with previous reports. Although the CoreHip Stem was originally designed to promote proximal bone ingrowth, distal spot welds were often observed in our cases. This finding may reflect strong distal fixation and reactive bone formation induced by the cancellous bone bed. In our experience, the CoreHip Stem is relatively easy to handle and has a wide range of clinical applications. Further long-term investigations are warranted to confirm our findings.

The THA cases using the CoreHip Stem showed favorable short-term clinical outcomes.